Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Verbeke, Len, Farre, Ricard, Trebicka, Jonel, Komuta, Mina, Roskams, Tania, Klein, Sabine, Elst, Ingrid Vander, Windmolders, Petra +3 more·2014·Hepatology
DOI 10.1002/hep.26939

Cited by (259)

Items 101–200 of 259

  1. Hepatic encephalopathy in acute-on-chronic liver failure
    Guan Huei Lee · 2015 · Hepatology International
  2. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module
    Sofie Marchsteiner Bendixen, Peter R. Jakobsgaard, Daniel Hansen, Kamilla H Hejn, Mike Krogh Terkelsen, Frederik Adam Bjerre, Annemette Præstegaard Thulesen, Niels G. Eriksen, Philip Hallenborg, Yana Geng et al. · 2023 · Journal of Hepatology
  3. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease
    Emina Halilbasic, Claudia Daniela Fuchs, Stefan Traussnigg, Michael Trauner · 2016 · Digestive Diseases
  4. DDAH2 suppresses RLR-MAVS–mediated innate antiviral immunity by stimulating nitric oxide–activated, Drp1-induced mitochondrial fission
    Shan Huang, Zexing Li, Zewen Wu, Chang Liu, Minghang Yu, Mingjie Wen, Liyun Zhang, Xi Wang · 2021 · Science Signaling
  5. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis
    Jane Macnaughtan, Rajiv Jalan · 2015 · The American Journal of Gastroenterology
  6. Portal Hypertension in Nonalcoholic Fatty Liver Disease: From Pathogenesis to Clinical Practice
    Saut Horas Hatoguan Nababan, Cosmas Rinaldi Adithya Lesmana · 2022 · Journal of Clinical and Translational Hepatology
  7. Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
    Stefano Fiorucci, Ginevra Urbani, Eleonora Distrutti, Michele Biagioli · 2025 · Pharmaceuticals
  8. New Therapies for Primary Biliary Cirrhosis
    Annarosa Floreani, Irene Franceschet, Lisa Perini, Nora Cazzagon, Merrill Eric Gershwin, Christopher L. Bowlus · 2014 · Clinical Reviews in Allergy & Immunology
  9. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis
    Denise van der Graaff, Wilhelmus Josephus Kwanten, Sven Francque · 2018 · Medical Hypotheses
  10. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction
    Wenxuan Xu, Chunfeng Lu, Feng Zhang, Jiangjuan Shao, Shunyu Yao, Shizhong Zheng · 2016 · FEBS Journal
  11. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system
    Ajit Dash, Robert A. Figler, B. Blackman, Svetlana Marukian, Maria Sol Collado, Mark J. Lawson, Stephen Aurelien Hoang, Aaron J. Mackey, David R. Manka, Banumathi K. Cole et al. · 2016 · Toxicology in Vitro
  12. Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway
    Junting Gong, Fan Yang, Qiaoling Yang, Xiaowen Tang, Fangfang Shu, Lieming Xu, Zhengtao Wang, Li Yang · 2019 · Journal of Natural Medicines
  13. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
    Weifang Huang, Desong Kong · 2021 · Biomedicine & Pharmacotherapy
  14. Management of Portal Hypertension
    Anand V. Kulkarni, Atoosa Rabiee, Arpan Mohanty · 2022 · Journal of Clinical and Experimental Hepatology
  15. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease
    Yali Liu, Tao Liu, Xu Min Zhao, Yanhang Gao · 2022 · Cellular and Molecular Life Sciences
  16. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model
    Liangshuo Hu, Lin Su, Zhixia Dong, Yunhua Wu, Yi Lv, Jacob George, Jianhua Wang · 2019 · Journal of Molecular Medicine
  17. Emerging medical therapies for severe alcoholic hepatitis
    Dávid Tornai, Gyöngyi Szabó · 2020 · Clinical and Molecular Hepatology
  18. Apigenin protects mice against 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestasis
    Shihong Zheng, Peichang Cao, Zequn Yin, Xuerui Wang, Yuanli Chen, Maoyun Yu, Baocai Xu, Chenzhong Liao, Yajun Duan, Shuang Zhang et al. · 2021 · Food & Function
  19. Targeting bile acid signaling for the treatment of liver diseases: From bench to bed
    Shuni Duan, Xiaojiaoyang Li, Guifang Fan, Runping Liu · 2022 · Biomedicine & Pharmacotherapy
  20. Novel treatment options for portal hypertension
    Philipp Schwabl, Wim Laleman · 2017 · Gastroenterology report
  21. Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
    Antonio De Vincentis, Daphne D’Amato, Laura Cristoferi, Alessio Gerussi, Federica Malinverno, Ana Lleò, Francesca Colapietro, Fabio Marra, Andrea Galli, Cecilia Fiorini et al. · 2022 · Liver International
  22. Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR‐S1PR2 ‐dependent mechanism
    Wenxuan Xu, Chunfeng Lu, Feng Zhang, Jiangjuan Shao, Shizhong Zheng · 2016 · IUBMB Life
  23. FXR Agonists: From Bench to Bedside, a Guide for Clinicians
    A. Alawad, C. Levy · 2016 · Digestive Diseases and Sciences
  24. Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids
    Ling Wang, Meng Li, Bingting Yu, Shaojun Shi, Jiaye Liu, Ruyi Zhang, Ibrahim Ayada, Monique M. A. Verstegen, Luc J. W. van der Laan, Maikel Petrus Peppelenbosch et al. · 2022 · Journal of Molecular Medicine
  25. Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges
    Anita Madir, Ivica Grgurević, Emmanuel A. Tsochatzis, Massimo Pinzani · 2024 · World Journal of Gastroenterology
  26. Farnesoid X receptor modulators (2011 – 2014): a patent review
    Valentina Sepe, Eleonora Distrutti, Stefano Fiorucci, Angela Zampella · 2015 · Expert Opinion on Therapeutic Patents
  27. 7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency
    Ali Nakhi, Connor M. McDermott, Kristen L. Stoltz, Kristen John, Jon E. Hawkinson, Elizabeth A. Ambrose, Alexander Khoruts, Michael Jay Sadowsky, Peter I. Dosa · 2019 · Journal of Medicinal Chemistry
  28. Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1
    Feng Zhang, Feixia Wang, Jianlin He, Naqi Lian, Zhenyi Wang, Jiangjuan Shao, Hai Ding, Shanzhong Tan, Anping Chen, Zili Zhang et al. · 2020 · British Journal of Pharmacology
  29. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis
    Dmitry Victorovich Garbuzenko · 2015 · World Journal of Gastroenterology
  30. Vascular targets for the treatment of portal hypertension
    Brusilovskaya, Ksenia, Königshofer, Philipp, Schwabl, Philipp, Reiberger, Thomas · 2019 · Seminars in Liver Disease
  31. Advances in therapeutic options for portal hypertension
    Marina Vilaseca, Sergi Guixé‐Muntet, Anabel Fernández‐Iglesias, Jordi Gracia‐Sancho · 2018 · Therapeutic Advances in Gastroenterology
  32. Treatment options for nonalcoholic steatohepatitis - a safety evaluation
    Danny Issa, Julia J. Wattacheril, Arun Jayant Sanyal · 2017 · Expert Opinion on Drug Safety
  33. Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis
    Daniela Gabbia, Arianna Dalla Pozza, Laura Albertoni, Roberta Lazzari, Giorgia Zigiotto, Maria Carrara, Vincenzo Baldo, Tatjana Baldovin, Annarosa Floreani, Sara De Martin · 2017 · World Journal of Gastroenterology
  34. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis
    Peter Hauff, Ulrich Gottwald, Matthias Ocker · 2014 · Expert Opinion on Investigational Drugs
  35. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
    Jie Zhao, Baozhen Li, Kai Zhang, Zhiyong Zhu · 2024 · Medicine
  36. Targeting the transsulfuration-H 2 S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension
    Stefano Fiorucci, Eleonora Distrutti · 2016 · Pharmacological Research
  37. Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases
    Yan Li, Lungen Lu · 2018 · Journal of Clinical and Translational Hepatology
  38. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease
    Sergi Guixé‐Muntet, Changpeng Zhu, Wei‐Fen Xie, Jordi Gracia‐Sancho · 2020 · Pharmacology & Therapeutics
  39. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats
    Hui‐Chun Huang, Ming-Hung Tsai, Ching-Chih Chang, Chon Kit Pun, Yi‐Hsiang Huang, Ming‐Chih Hou, Fa‐Yauh Lee, Shao‐Jung Hsu · 2021 · Clinical Science
  40. Hepatic SIRT6 Modulates Transcriptional Activities of FXR to Alleviate Acetaminophen-induced Hepatotoxicity
    Changhui Liu, Zhisen Pan, Zhou-Li Wu, Kaijia Tang, Yadi Zhong, Yingjian Chen, Xiaoxia Xiao, Jingyi Guo, Siwei Duan, Tianqi Cui et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
  41. The role of the gut microbiome and its metabolites in cerebrovascular diseases
    Hongyu Xu, Ziyue Xu, Shengrong Long, Zhengwei Li, Jiazhi Jiang, Qiangqiang Zhou, Xiaopeng Huang, Xiaohui Wu, Wei Wei, Xiang Li · 2023 · Frontiers in Microbiology
  42. FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
    Benedikt Simbrunner, Benedikt Hofer, Philipp Schwabl, Kerstin Zinober, Oleksandr Petrenko, Claudia Daniela Fuchs, Georg Semmler, Rodrig Marculescu, Mattias Mandorfer, Christian Datz et al. · 2024 · Hepatology International
  43. Steroidal or non-steroidal FXR agonists – Is that the question?
    Len Verbeke, Frederik Nevens, Wim Laleman · 2017 · Journal of Hepatology
  44. Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications
    Luyuan Chang, Yang Liu, Haipeng Li, Jiaqi Yan, Wei Wu, Nuo Chen, Chunyu Ma, Xinyi Zhao, Juan Chen, Jing Zhang · 2025 · Frontiers in Cellular and Infection Microbiology
  45. Emerging therapies for portal hypertension in cirrhosis
    Harikumar R. Nair, Annalisa Berzigotti, Jaime Bosch · 2016 · Expert Opinion on Emerging Drugs
  46. Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms
    Heming Ma, Xu Liu, Mingyuan Zhang, Junqi Niu · 2021 · Molecular Biology Reports
  47. Bile-ology: from bench to bedside
    Lihua Jin, Zhipeng Fang, Min-jie Fan, Wendong Huang · 2019 · Journal of Zhejiang University SCIENCE B
  48. Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury
    Li Ren, Qing Song, Yunhuan Liu, Lihua Zhang, Zhiming Hao, Wenke Feng · 2019 · Biochemical and Biophysical Research Communications
  49. Metformin alleviates irradiation-induced intestinal injury by activation of FXR in intestinal epithelia
    Jing-Yu Yang, Mengjie Liu, Lin Li Lv, Jin-Rong Guo, Kai-Yue He, Hong Zhang, Keke Wang, Cui-Yun Cui, Beizhan Yan, Dandan Du et al. · 2022 · Frontiers in Microbiology
  50. Future therapy of portal hypertension in liver cirrhosis – a guess
    Tilman Sauerbruch, Jonel Trebicka · 2014 · F1000Prime Reports
  51. Emerging Therapeutic Targets for Portal Hypertension
    Éric Felli, Yelidousi Nulan, Sonia Emilia Selicean, Cong Wang, Jordi Gracia‐Sancho, Jaime Bosch · 2023 · Current Hepatology Reports
  52. Liver Capsule: FXR agonists against liver disease
    Fuchs, Claudia D., Schwabl, Peter, Reiberger, Thomas, Trauner, Michael · 2016 · Hepatology
  53. Recent updates on alcoholic hepatitis
    Lindsey C. Shipley, Sudha Kodali, Ashwani K. Singal · 2019 · Digestive and Liver Disease
  54. Bile Acids and Portal Hypertension
    Juan Pablo Arab, Francisco Barrera M., Marco A. Arrese · 2017 · Annals of Hepatology
  55. Farnesoid X receptor: a potential therapeutic target in multiple organs.
    Chao Zhang, Zixuan Wang, Q. Feng, Wei-Dong Chen, Yan-Dong Wang · 2021 · Histology and Histopathology
  56. Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis
    Thoetchai Bee Peeraphatdit, Douglas Alano Simonetto, Vijay H. Shah · 2018 · Journal of Hepatology
  57. Pathophysiology and a Rational Basis of Therapy
    Jordi Gracia‐Sancho, Raquel Maeso‐Díaz, Jaime Bosch · 2015 · Digestive Diseases
  58. The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing
    Kai Kou, Xiaodong Sun, Guangyao Tian, Zhi Yao, Zhongqi Fan, Guoyue Lv · 2022 · Journal of Immunology Research
  59. Evolving therapies for non-alcoholic steatohepatitis
    Herbert Tilg, Alexander Rupert Moschen · 2014 · Expert Opinion on Drug Discovery
  60. Obeticholic acid for the treatment of primary biliary cirrhosis
    David E. Jones · 2016 · Expert Review of Gastroenterology & Hepatology
  61. Stellate Cells and Hepatic Fibrosis
    Daisuke Hasegawa, Michael C. Wallace, Scott L. Friedman · 2015 · Elsevier eBooks
  62. Current and Emerging Approaches for Hepatic Fibrosis Treatment
    Jingguo Li, Biguang Tuo · 2021 · Gastroenterology Research and Practice
  63. The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure
    Anna Maria Czarnecka, Krzysztof Milewski, Jan Albrecht, Magdalena Zielińska · 2020 · International Journal of Molecular Sciences
  64. Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
    Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca V. C. Valenti, Xiaolong Qi, Ming‐Hua Zheng · 2022 · Portal hypertension & cirrhosis
  65. Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis
    Azizsoltani, Arezou, Niknam, Bahare, Taghizadeh-Teymorloei, Mohammad, Ghoodjani, Erfan, Dianat-Moghadam, Hassan, Alizadeh, Effat · 2025 · Biomedicine & Pharmacotherapy
  66. Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?
    Anna Maria Czarnecka, Krzysztof Milewski, Magdalena Zielińska · 2016 · Neurochemical Research
  67. A time- and space-resolved nuclear receptor atlas in mouse liver
    Francesco Paolo Zummo, Alexandre Berthier, Céline Gheeraert, Manjula Vinod, Marie Bobowski, Olivier Molendi‐Coste, Laurent Pineau, Matthieu Jung, Loïc Guille, Julie Dubois‐Chevalier et al. · 2023 · Journal of Molecular Endocrinology
  68. Mechanisms of portal hypertension: Bench to bedside
    Jordi Gracia‐Sancho, Wim Laleman · 2016 · Clinical Liver Disease
  69. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats
    Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Chen Wang · 2019 · Frontiers of Medicine
  70. Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.
    Zhiyu Yang, Feng Liu, Peihao Liu, Wan-Jun Guo, Guo-Yu Xiong, Hai‐Feng Pan, Lai Wei · 2017 · PubMed Central
  71. New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target
    Yunqi Xing, Yanghao Ou, Yujie Wang, Luming Hou, Junfeng Zhu · 2025 · Biochemical Pharmacology
  72. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
    Eric Kalo, Scott A. Read, Golo Ahlenstiel · 2021 · Livers
  73. Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
    Maria Effenberger, Christoph Grander, Felix Grabherr, Herbert Tilg · 2023 · Journal of Clinical and Translational Hepatology
  74. Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer
    Lin Guan, Peng Miao · 2020 · European Journal of Pharmacology
  75. Emerging Therapies for Nonalcoholic Fatty Liver Disease
    Bilal Hameed, Norah A. Terrault · 2016 · Clinics in Liver Disease
  76. Research progress on signaling pathways in cirrhotic portal hypertension
    Wenping Xu, Ping Liu, Yongping Mu · 2018 · World Journal of Clinical Cases
  77. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
    Georg Semmler, Benedikt Simbrunner, Bernhard Scheiner, Philipp Schwabl, Rafael Paternostro, Theresa Bucsics, Albert Friedrich Stättermayer, David Josef Maria Bauer, Matthias Pinter, Péter Ferenci et al. · 2019 · Journal of Gastroenterology and Hepatology
  78. 3D‐Printed Lipid Mesophases for the Treatment of Chronic Liver Disease
    Marianna Carone, Rafaela Pletsch Gazzi, Remo Eugster, Rita Gelli, Niklaas Manten, Aymar Abel Ganguin, Silvia Di Valerio, Garima Yadav, Pasqualina Castaldo, Raffaele Mezzenga et al. · 2024 · Advanced Materials Technologies
  79. Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension
    Peio Aristu-Zabalza, María Andrés‐Rozas, Zoe Boyer‐Díaz, David P. Al‐Adra, Douglas Maya‐Miles, Sergi Guixé‐Muntet, Anabel Fernández‐Iglesias, Jordi Gracia‐Sancho · 2025 · Biology of Sex Differences
  80. Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis
    Tongyao Wang, Xingyu Rong, Chao Zhao · 2022 · Frontiers in Cellular and Infection Microbiology
  81. Current and emerging therapies for alcohol-associated hepatitis
    Francisco Javier Idalsoaga, Gustavo Ayares, Luis Antonio Díaz, Jorge Arnold, María Ayala-Valverde, David Hudson, Marco A. Arrese, Juan Pablo Arab · 2023 · Liver Research
  82. Recent advances in understanding/management of non-alcoholic steatohepatitis
    Tommy Pacana, Arun Jayant Sanyal · 2015 · F1000Prime Reports
  83. Current Treatment Options for Primary Biliary Cholangitis
    Kimberly A. Wong, Runalia Bahar, Chung H. Liu, Christopher L. Bowlus · 2018 · Clinics in Liver Disease
  84. Roles of nuclear receptors in hepatic stellate cells
    Shiyun Pu, Hongjing Zhou, Yan Liu, Jiao Liu, Yuanxin Guo, Houfeng Zhou · 2021 · Expert Review of Gastroenterology & Hepatology
  85. Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
    Aizhen Xiong, Longhui Lu, Kaiyuan Jiang, Xiaoning Wang, Yan Chen, Xunjiang Wang, Wei Zhang, Yuzheng Zhuge, Wendong Huang, Lujin Li et al. · 2024 · Archives of Toxicology
  86. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension
    Michał Porada, Łukasz Bułdak · 2025 · Metabolites
  87. Aspects of pathogenetic pharmacotherapy for portal hypertension in liver cirrhosis
    Dmitry Victorovich Garbuzenko · 2016 · Terapevticheskii arkhiv
  88. Structural basis for the hepatoprotective effects of antihypertensive 1,4-dihydropyridine drugs
    Yijuan Wei, Yi Ping Lu, Yanlin Zhu, Weili Zheng, Fusheng Guo, Benqiang Yao, Shuangshuang Xu, Yumeng Wang, Lihua Jin, Yong Li · 2018 · Biochimica et Biophysica Acta (BBA) - General Subjects
  89. New mechanistic insights into hepatoprotective activity of milk thistle and chicory quantified extract: The role of hepatic Farnesoid-X activated receptors.
    Azadeh Khalili, Parviz Fallah, Seyed Ali Hashemi, Mohammad Mahdi Ahmadian-Attari, Vahid Jamshidi, Roham Mazloom, Leila Beikzadeh, Gholamreza Bayat · 2021 · PubMed Central
  90. Therapeutic Pipeline in Alcohol-Associated Liver Disease
    Nimish Thakral, Sasha Deutsch‐Link, Ashwani Kumar Singal · 2022 · Seminars in Liver Disease
  91. Treatment of Primary Biliary Cholangitis
    Liu, Chung-Heng, Bowlus, Christopher L. · 2022 · Clinics in Liver Disease
  92. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: A preliminary study
    Lai Wei, Juan Yang, Min Wang, Shengnan Xu, Huamin Liang, QI ZHOU · 2014 · International Journal of Molecular Medicine
  93. Future Medical Treatment of PSC
    Elisabeth Krones, Hanns–Ulrich Marschall, Peter Fickert · 2019 · Current Hepatology Reports
  94. Emerging Therapies for Alcoholic Hepatitis
    Ma Ai Thanda Han, Nikolaos Pyrsopoulos · 2021 · Clinics in Liver Disease
  95. Nuclear receptors: how do they position in non‐alcoholic fatty liver disease treatment?
    Mariana Verdelho Machado, Helena Cortez‐Pinto · 2014 · Liver International
  96. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives
    Stefano Gitto, Valeria Guarneri, Alessandro Sartini, Pietro Andreoné · 2017 · Expert Review of Gastroenterology & Hepatology
  97. Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis
    Kazuaki Tajima, Satoshi Miuma, Hisamitsu Miyaaki, Satoshi Matsuo, Akane Shimakura, Tomotaka Mori, Kosuke Takahashi, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi et al. · 2024 · Hepatology Research
  98. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Vinay Sundaram, Timothy R.M. Morgan · 2018 · Clinics in Liver Disease
  99. Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
    Bing Han, Huan Tang, Qiming Liang, Ming Ji Zhu, Yizhuo Xie, Jinglin Chen, Qianwen Li, Juan Jia, Yan Li, Zhihui Ren et al. · 2021 · Drug Delivery
  100. Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management
    Francesco Santopaolo, Gaetano Coppola, Lucia Giuli, Antonio Gasbarrini, Francesca Romana Ponziani · 2022 · Microbiology Research